Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
May 1, 2019 4:05 PM EDT
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18
-
Updated 2019 Net Sales Guidance to $280 Million to $300 Million
-
Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies
with Pimavanserin
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2019.
Weve commenced 2019 with significant momentum. The... More
